Does MiR-30 promote fatty acid beta-oxidation and endothelial cell dysfunction in pre-clinical models of diabetes?
MiR-30d/e may serve as early biomarkers and therapeutic targets for coronary microvascular and diastolic dysfunction in diabetic hearts.
MiR-30d/e represent early biomarkers and potential therapeutic targets that are indicative of the development of diastolic dysfunction and may reflect altered EC fatty acid metabolism and microvascular dysfunction in the diabetic heart.
Veitch et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: